@article{ATM25535,
author = {Dylan M. Buller and Benjamin T. Ristau},
title = {Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 3},
year = {2019},
keywords = {},
abstract = {From 2007 to 2011, the adjuvant sunitinib in high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC) investigators conducted a phase 3, randomized, placebo-controlled trial with primary results published in 2016 (1). Patients with completely resected, high-risk RCC defined based on pathologic stage received either adjuvant sunitinib or placebo for a maximum of 1 year.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/25535}
}